钠-葡萄糖协同转运蛋白2抑制剂降糖作用外肾脏保护机制研究进展

Research progress on the renal protective mechanisms of sodium-dependent glucose transporters 2 inhibitors except hypoglycemic effect

钠-葡萄糖协同转运蛋白2(sodium-dependent glucose transporters 2,SGLT2)抑制剂(SGLT2 inhibition, SGLT2i)是全新机制的降糖药物,它与肾小管葡萄糖重吸收相关。在大规模随机对照试验中,SGLT2i在肾脏保护方面可降低终末期肾病、肾透析、肾移植等事件风险,对于肾脏的保护作用远远超出了其对于血糖的影响。考虑到其他具有更强的降糖效果的药物并未出现类似的获益,SGLT2i显然具有降糖外的肾脏保护机制,这也是目前临床治疗和研究的热点,本文综述其相关作用与机制。

Sodium-dependent glucose transporters 2 inhibitors(SGLT2 i), as a new hypoglycemic drugs, are associated with renal tubular reabsorption of glucose. In several large-scale clinical randomized controlled trials, SGLT2 i decreased the incidence of end-stage renal disease and the demand for dialysis or transplantation due to kidney disease. Its renoprotective effect is far beyond its hypoglycemic effect. Considering that other drugs with stronger hypoglycemic effect have not gained similar benefits, SGLT2 i obviously has a renal protective mechanism outside hypoglycemic effect, becoming the hot spot for clinical treatment and research field at present. In this paper, the relevant functions and mechanisms are reviewed.